✦ LIBER ✦

Optimizing the dasatinib dose regimen in chronic phase chronic myeloid leukemia: 100 mg once daily available for use

✍ Scribed by Ravi Vij

Book ID: 118628097
Publisher: Frontline Medical Communications, Inc.
Year: 2009
Tongue: English
Weight: 63 KB
Volume: 6
Category: Article
ISSN: 1548-5315
DOI: 10.1016/s1548-5315(11)70371-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib 100 mg once daily minimizes th

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

✍ Kimmo Porkka; H. Jean Khoury; Ronald L. Paquette; Yousif Matloub; Ritwik Sinha; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

PCN14 THE COST AND COST EFFECTIVENESS OF

PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICO

✍ Juarez-Garcia, A; Uc-Coyoc, R; Hernandez-Rivera, G; Rangel, S; Taylor, MJ; Lital 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Phase III, Randomized, Open-Label Study

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

✍ Cortes, J. E.; Baccarani, M.; Guilhot, F.; Druker, B. J.; Branford, S.; Kim, D.- 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 166 KB